AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window There was a ...

AstraZeneca has completed all clinical studies required to support the first filings for the transition of its chronic ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Jennifer Trevor, M.D., associate professor in the UAB Division of Pulmonary, Allergy, and Critical Care Medicine, directs the Severe Asthma Clinic at UAB. In order to provide her patients with access ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...